BioMavericks

Cancer is ranked at the top of global burden of disease, impelling the growth of the global oncology therapeutics market to a size of $250 billion by 2025. Upon pandemic, the liquid biopsy sub-sector has come to the spotlight with a compound annual growth rate of 38.5% for the next four years, paving the way for business development in early cancer diagnosis. While current cancer diagnostics relies on canonical cancer markers that are hardly expressed at early stages, we have leveraged the most advanced technology along with our proprietary pipelines to detect early cancers. Unlike our competitors who selectively capture a subset of cells from peripheral blood, we have developed new testing products to detect and profile all critical cell types in the blood with high sensitivity and specificity. Our products can provide new information on the molecular characteristics of cancer cells and infer tumour locations and metastasis sites. These unique features revolutionise the concept of early cancer diagnosis and are critical for both patients and doctors for personalised medicine. So far, we have a team of six people with diverse backgrounds and expertise and incorporate a new company named BioMavericks.

Get in touch

Visit BioMavericks' website